NCT03975153View on ClinicalTrials.gov

Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 3, 2019

Primary Completion Date

August 11, 2022

Study Completion Date

March 22, 2024

Conditions
Pityriasis Rubra Pilaris
Interventions
BIOLOGICAL

guselkumab

Treatment at the FDA-approved psoriasis dosing for 20 weeks

Trial Locations (1)

97239

Oregon Health and Science University, Portland

All Listed Sponsors
lead

Oregon Health and Science University

OTHER

NCT03975153 - Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP) | Biotech Hunter | Biotech Hunter